Selpercatinib Production Cost Reports

The report provides a detailed analysis essential for establishing a selpercatinib production plant. It encompasses all critical aspects necessary for selpercatinib production, including the cost of selpercatinib production, selpercatinib plant cost, selpercatinib production costs, and the overall selpercatinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a selpercatinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Selpercatinib is an oral targeted cancer drug that blocks faulty RET gene signals, causing specific lung, thyroid, and other tumours to grow. It treats advanced RET-changed non-small cell lung cancer as first or later-line therapy with high response rates of around 64% in new patients. It is also utilised in RET-mutant medullary thyroid cancer in adults and kids over age 2 needing systemic treatment, showing 44-69% responses.

It finds its application in radioactive iodine-resistant RET fusion thyroid cancers and any progressing solid tumour with RET fusions when other options fail. It works precisely on cancer cells without harming normal ones much, filling gaps for rare gene-driven cancers. Its common side effects include dry mouth, diarrhoea, tiredness and fatigue, swelling and oedema, constipation, etc.

The market for selpercatinib is fuelled by growing RET-driven cancer diagnoses. The growing NGS biomarker testing enabling precision matching, label expansions to first-line NSCLC and pediatric MTC, and better efficiency over chemo fuels its market. Its global approvals across many countries, rise in personalised oncology, along with advanced diagnostics and advances in new solid tumours and combos contributes to its market demand.

The industrial selpercatinib procurement is influenced by diagnostic access for RET confirmation, high pricing and reimbursement problems,  and GMP-certified API sourcing. Also, competition from other alternatives like pralsetinib and hospital budget constraints for targeted therapies impact its sourcing strategies.

Raw Material for Selpercatinib Production

According to the selpercatinib production plant project report, the key raw materials used in the production of selpercatinib include substituted pyridine, electrophilic nitrogen source, and chloroacrylonitrile.

Production Process of Selpercatinib

The extensive selpercatinib production cost report consists of the following major industrial production process:

1. From substituted pyridine: The production of selpercatinib starts with a functionalised pyrazolopyridine core from a substituted pyridine via an electrophilic nitrogen source and three-carbon cyclisation. After that, the core is sequentially modified by demethylation and triflation, performing a Suzuki coupling to append a substituted pyridine fragment. This introduces the ethereal side chain using a palladium-catalysed reaction with an epoxide. Finally, the azabicyclic moiety is installed by nucleophilic aromatic substitution to get selpercatinib as the final product.

Selpercatinib has the molecular formula of C29H31N7O3 and a molecular weight of 525.61 g/mol. It appears as a white to off-white solid with a logP value of 3-4, making it lipophilic. It has a topological polar surface area of around 103 Å with high protein binding (97%). It shows low water solubility, having a pyrazolo[1,5-a]pyridine core, diazabicyclo[3.1.1]heptane linker, methoxypyridine, and hydroxypropoxy sidechain. Its complexity supports kinase selectivity while TPSA aids GI absorption per prior rules, consistent with oncology small molecules. All these physical and chemical properties makes it useful as an oral targeted cancer drug.